CD4 and neoplasm: Via flow cytometry, the proportions of CD4+ T cells and CD8+ T cells in the BEV@BMDCs group dramatically raised 21.7‐fold and 16.3‐fold in tumor tissues compared with the control group, respectively (Figure 4f; Figure S10, Supporting Information).